Scilex Holding (SCLXW) Shares Outstanding (Weighted Average) (2020 - 2026)
Scilex Holding (SCLXW) recorded quarterly Shares Outstanding (Weighted Average) of $6.9 million in Q1 2026, up 4311.09% quarter-over-quarter from $156220.0 in Q4 2025, and down 40.42% on a YoY basis from $11.6 million in Q1 2025.
Scilex Holding (SCLXW) Shares Outstanding (Weighted Average) (2020 - 2026) Analysis & Trends
Scilex Holding's Shares Outstanding (Weighted Average) history runs 7 years deep, the most recent figure standing at $6.9 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Weighted Average) fell 40.42% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $6.9 million (down 40.42% YoY), while the FY2025 annual figure was $156220.0, changed 0.0% from the prior year.
- Shares Outstanding (Weighted Average) was $6.9 million for Q1 2026 at Scilex Holding, up from $156220.0 in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $134.2 million in Q4 2022 to a low of $2926.0 in Q1 2024.
- Historically, Shares Outstanding (Weighted Average) has averaged $40.5 million across 5 years, with a median of $156220.0 in 2024.
- The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Weighted Average) slumped 99.89% in 2023, then jumped 395149.49% in 2025.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $134.2 million in 2022, then decreased by 2.93% to $130.3 million in 2023, then slumped by 99.88% to $156220.0 in 2024, then changed by 0.0% to $156220.0 in 2025, then surged by 4311.09% to $6.9 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $6.9 million (Q1 2026), $156220.0 (Q4 2025), and $156115.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 1,818,692.66 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 894.50 Mn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 2.41 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 1.77 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 2.47 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 540.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 1.24 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 5.69 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 2.04 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn | 6.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.89 Mn |
| Dec 31, 2025 | 156,220.00 |
| Sep 30, 2025 | 156,115.00 |
| Jun 30, 2025 | 5.47 Mn |
| Mar 31, 2025 | 11.57 Mn |
| Dec 31, 2024 | 156,220.00 |
| Sep 30, 2024 | 7,557.00 |
| Jun 30, 2024 | 4,901.00 |
| Mar 31, 2024 | 2,926.00 |
| Dec 31, 2023 | 130.30 Mn |
| Sep 30, 2023 | 139,808.00 |
| Jun 30, 2023 | 142,146.00 |
| Mar 31, 2023 | 141,660.00 |
| Dec 31, 2022 | 134.23 Mn |
| Sep 30, 2022 | 133.06 Mn |
| Jun 30, 2022 | 133.04 Mn |
| Mar 31, 2022 | 133.03 Mn |
| Dec 31, 2021 | 132.86 Mn |
| Sep 30, 2021 | 17.25 Mn |
| Jun 30, 2021 | 16.39 Mn |